Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
Vera Golder(Monash University), Eric F. Morand(Novartis (Switzerland)), Masayoshi Harigai(Tokyo Medical and Dental University), Mandana Nikpour(University of Melbourne), Hieu T. Nim(Monash University), Sandra Navarra(University of Santo Tomas), Alberta Hoi(Monash Health), Madelynn Chan(Tan Tock Seng Hospital), Leonid Zamora(University of Santo Tomas Hospital), Yeong‐Jian Jan Wu(Chang Gung Memorial Hospital), Yasuhiro Katsumata(Tokyo Women's Medical University), Fiona Goldblatt(Royal Adelaide Hospital), Worawit Louthrenoo(Chiang Mai University), Laniyati Hamijoyo(Padjadjaran University), Rangi Kandane‐Rathnayake(Monash University), Sargunan Sockalingam(University of Malaya), Aisha Lateef(National University Hospital), Molla Huq(University of Melbourne), Zhan Guo Li(Peking University), Sean O’Neill(UNSW Sydney), Shue Fen Luo(Chang Gung Memorial Hospital), Chak Sing Lau(University of Hong Kong)
Cited by 161
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726